Rein Therapeutics (RNTX) Change in Acquisitions & Divestments (2016 - 2023)

Rein Therapeutics (RNTX) has reported Change in Acquisitions & Divestments for 8 consecutive years, with $500000.0 the latest figure, recorded in Q3 2023.

• In Q3 2023, Change in Acquisitions & Divestments fell 95.83% year-over-year to $500000.0; the TTM figure through Jun 2024 stood at $500000.0 (down 98.55% YoY), while the FY2023 annual figure was $16.2 million, down 66.36% from the prior year.
• Change in Acquisitions & Divestments fell to $500000.0 in Q3 2023 per RNTX's latest filing, from $8.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $23.8 million in Q3 2021 and bottomed at $500000.0 in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $7.5 million across 5 years, with a median of $7.0 million in 2019.
• Annual changes were most pronounced in 2021 — Change in Acquisitions & Divestments jumped 1257.2% — and 2023, when it plunged 95.83%.
• Rein Therapeutics' Change in Acquisitions & Divestments stood at $7.5 million in 2019, then tumbled by 80.02% to $1.5 million in 2020, then soared by 233.33% to $5.0 million in 2021, then jumped by 34.04% to $6.7 million in 2022, then slumped by 92.54% to $500000.0 in 2023.
• Business Quant data shows RNTX's Change in Acquisitions & Divestments at $500000.0 in Q3 2023, $8.5 million in Q2 2023, and $7.2 million in Q1 2023.